Frazier Life Sciences Management L.P. acquired 1,015,693 shares of Relay Therapeutics.
The new position is valued at approximately $19 million according to a recent SEC filing.
This stake represents roughly 0.46% of the clinical-stage precision medicine company.
The institutional investment signals a significant vote of confidence in the firm.
This disclosure follows recent share sales by the company CEO and a major shareholder.